Welcome to our dedicated page for Rapport Therapeutics SEC filings (Ticker: RAPP), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The SEC filings page for Rapport Therapeutics, Inc. (Nasdaq: RAPP) provides access to the company’s official regulatory disclosures as a clinical-stage biotechnology issuer. Rapport’s common stock is registered under Section 12(b) of the Securities Exchange Act of 1934 and listed on The Nasdaq Global Market under the symbol RAPP, so its filings offer detailed information on its precision neuroscience business and capital markets activity.
Through this page, readers can review Form 10-K and Form 10-Q reports (when filed) for discussions of Rapport’s RAP technology platform, the development of RAP-219 for drug-resistant focal onset seizures, bipolar mania, and diabetic peripheral neuropathic pain, and additional programs in chronic pain, migraine, and hearing or vestibular disorders. These periodic reports also describe risk factors, research and development expenses, and other elements of the company’s operating profile.
Frequent Form 8-K filings from RAPP document material events such as positive Phase 2a trial results for RAP-219 in focal onset seizures, new data analyses presented at scientific meetings, public offerings of common stock under an effective shelf registration statement on Form S-3, and quarterly financial results and business updates. Some 8-Ks also summarize regulatory developments, including clinical holds, end-of-Phase 2 planning, and changes to at-the-market sales arrangements.
Investors can also use this page to locate information related to shareholder meetings and voting outcomes, as disclosed in 8-K items covering submissions of matters to a vote of security holders. Insider transaction reports on Form 4, when available, complement these filings by showing equity activity by directors and officers.
Stock Titan enhances these documents with AI-powered summaries that explain key points from lengthy filings, highlight clinical and financial milestones, and make it easier to understand how new disclosures may relate to Rapport’s RAP-219 program and broader precision neuroscience pipeline. Real-time updates from EDGAR help ensure that new RAPP filings, including 10-K, 10-Q, 8-K, and Form 4 submissions, are quickly accessible in one place.
Rapport Therapeutics (RAPP) Amendment No. 1 to Schedule 13D reports that a Sofinnova group of entities and individuals collectively now beneficially own 1,863,327 shares of Common Stock, representing 4.0% of the outstanding shares based on 46,113,062 shares outstanding after the offering. The filing explains that Sofinnova Venture Partners XI originally acquired 11,924,138 Series B shares for $19,999,999 which converted into Common Stock at a 1-for-8.5648 ratio at the IPO. SVP XI separately purchased 470,589 shares in a private placement for $8,000,013 at $17.00 per share. The reporting persons state they ceased to be beneficial owners of more than 5% due to dilution from issuer share sales and confirm lock-up, investor rights and registration arrangements. The filing lists additional small open-market purchases and distributions and discloses a director stock option of 21,850 shares at $10.95 (vesting by June 17, 2026).
Rapport Therapeutics, Inc. (RAPP) filed a Form 144 reporting a proposed sale of 52,501 common shares, representing part of its outstanding stock, with an aggregate market value of $1,375,001.19. The sale is to be handled through Morgan Stanley Smith Barney LLC on NASDAQ with an approximate sale date of 09/17/2025. The shares were acquired on 12/02/2022 under an RSA from the issuer. The filer reports no securities sold in the past three months and provides the standard attestation about material nonpublic information.
Form 144 notice for Rapport Therapeutics, Inc. (RAPP) reports a proposed sale of 45,751 common shares through Morgan Stanley Smith Barney LLC on 09/17/2025 on NASDAQ with an aggregate market value of $1,198,218.69. The shares were acquired from the issuer under an RSA on 06/10/2024, and no securities were reported sold in the prior three months by the selling person. The filing includes the seller's representation that they are not aware of any undisclosed material adverse information about the issuer. This notice provides the broker, share count, acquisition details, planned sale date, and aggregate value as required under Rule 144.
Rapport Therapeutics, Inc. reported that Chief Scientific Officer David Bredt sold a total of 8,500 shares of common stock on September 15, 2025, in open-market or private transactions under a Rule 10b5-1 trading plan adopted on December 12, 2024. The sales were executed at weighted-average prices of $23.8841 and $24.6583 per share across multiple trades at prices ranging from $23.42 to $24.41 and from $24.42 to $24.90. Following these sales, Bredt held 418,142 shares of common stock directly.
Rapport Therapeutics director Reid M. Huber purchased 20,400 shares of RAPP common stock on 09/12/2025 at a weighted-average price of $24.4791 per share, with transaction prices ranging from $24.23 to $24.50. After the purchase Huber beneficially owns 20,400 shares directly. No derivative securities were reported. The Form 4 was signed by an attorney-in-fact on behalf of the reporting person on 09/15/2025. The filer notes the reported price is a weighted average and offers to provide a breakdown of the individual trade prices on request.
Director Paul Steven M reported purchases of Rapport Therapeutics, Inc. (RAPP) common stock on 09/12/2025. Two purchase entries show 28,284 shares at a weighted average price of $24.4996 and 13,382 shares at a weighted average price of $24.9712, for a combined 41,666 shares. Both holdings are reported as indirect ownership through Paul Capital Strategy III Fund LLC, with the reporting person disclaiming beneficial ownership except to the extent of any pecuniary interest. The filing discloses the price ranges for the multiple trades that produced the weighted averages and is signed by an attorney-in-fact on behalf of the reporting person.
Wendy B. Young, a director of Rapport Therapeutics, Inc. (RAPP), reported a purchase of 3,500 shares of the company's common stock on 09/11/2025 at a reported price of $22.60 per share. After this transaction she beneficially owns 9,500 shares. The Form 4 filing was signed by an attorney-in-fact on 09/11/2025.
Rapport Therapeutics, Inc. (RAPP) disclosed a marketed offering of common stock to be sold by the company, with all shares in the offering sold by Rapport. The company states the offering is expected to close on or about September 11, 2025, subject to customary closing conditions.
The filing references a previously filed S-3 (file no. 333-288444) declared effective on July 9, 2025, and a final prospectus supplement dated September 9, 2025 filed on September 10, 2025. An underwriting agreement dated September 9, 2025 names Goldman Sachs, Jefferies, TD Securities (USA) and Stifel as bookrunners. The filing also notes legal opinion and consent from Goodwin Procter LLP and includes Inline XBRL cover page data.
Rapport Therapeutics (RAPP) is offering common stock at $26.00 per share, with aggregate dollar figures shown of $250,000,010.00 and related underwriting allocations. The prospectus describes RAP-219, an AMPAR negative allosteric modulator targeting TARPγ8 for focal epilepsy, bipolar disorder and peripheral neuropathic pain. In an 8-week Phase 2a cohort of 30 patients, RAP-219 showed topline efficacy: 85.2% of patients achieved ≥30% reduction in LEs (p<0.0001), 72.0% achieved ≥50% reduction in clinical seizures (p<0.0001), and a reported 24% figure for seizure outcome in the 8-week period (p<0.0001). Safety: four discontinuations during treatment, three due to TEAEs; safety population = 30. A PET trial and MAD-2 supported target receptor occupancy and neuroanatomical specificity. The FDA placed the IND for a DPNP proof-of-concept trial on clinical hold in Q4 2024; this hold is LIMITED to DPNP and has not affected the focal epilepsy Phase 2a or planned bipolar trial. Company timelines: initiate open-label long-term safety trial by end of 2025 (prelim results H2 2026), advance two Phase 3 pivotal trials in Q3 2026, and report PK results in 2027. The prospectus notes broad management discretion over net proceeds and typical lock-up and transfer restrictions for insiders.
Rapport Therapeutics insider Cheryl Gault, the company's Chief Operating Officer, reported transactions on 09/08/2025 under a Rule 10b5-1 trading plan adopted December 11, 2024. The Form 4 shows a simultaneous option exercise and sale: 5,000 shares were acquired by exercise of stock options at an exercise price of $1.80 per share and 5,000 shares were sold the same day at $38.33 per share.
After these transactions Ms. Gault directly beneficially owns 171,928 shares of common stock and holds 110,407 shares underlying outstanding options. The option grant vests 25% on August 7, 2024, with the remainder vesting monthly over 36 months, and the exercised options expire December 5, 2033.